RS51073B - Proces za pripremanje (3r,3as,6ar)-heksahidrofuro│2,3-b│ furan-3-il (1s,2r)-3-││(4-aminofenil) sulfonil│(izobutil) amino │-1-benzil-2-hidroksipropilkarbamata - Google Patents

Proces za pripremanje (3r,3as,6ar)-heksahidrofuro│2,3-b│ furan-3-il (1s,2r)-3-││(4-aminofenil) sulfonil│(izobutil) amino │-1-benzil-2-hidroksipropilkarbamata

Info

Publication number
RS51073B
RS51073B YUP-2009/0404A YUP20090404A RS51073B RS 51073 B RS51073 B RS 51073B YU P20090404 A YUP20090404 A YU P20090404A RS 51073 B RS51073 B RS 51073B
Authority
RS
Serbia
Prior art keywords
formula
compound
hexahydrofuro
furan
benzyl
Prior art date
Application number
YUP-2009/0404A
Other languages
English (en)
Inventor
Nicolaas Martha Felix Goyvaerts
Piet Tom Bert Paul Wigerinck
Hartmut Burghard Zinser
Birgit M. Ebert
Original Assignee
Tibotec Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43827001&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51073(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharmaceuticals Ltd. filed Critical Tibotec Pharmaceuticals Ltd.
Priority claimed from PCT/EP2004/053692 external-priority patent/WO2005063770A1/en
Publication of RS51073B publication Critical patent/RS51073B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Proces za pripremanje jedinjenja sa formulom (6)njegovih adicijskih soli, polimorfnih i/ili pseudopolimorfnih formi, naznačen time, da pomenuti proces obuhvata korake:(i) uvođenja izobutilamino grupe ujedinjenje sa formulom (1');sa ciljem dobivanja jedinjenj a sa formulom (2');(ii) uvođenja p-nitrofenilsulfonilne grupe ujedinjenje sa formulom (2') sa ciljem da se dobije jedinjenje sa formulom (3');(iii) reduciranja nitro ostatka iz jedinjenja sa formulom (3') sa ciljem da se dobije jedinjenje sa formulom (4');(iv) otklanjanja zaštite sa jedinjenja sa formulom (4') sa ciljem da se dobije jedinjenje sa formulom (5);spajanja jedinjenja sa formulom (5) sa derivatom (3R,3aS,6aR)-heksahidrofuro [2,3-b] furan-3-il, koji je dobiven aktivisanjem (3R,3aS,6aR)-heksahidrofuro [2,3-b] furan-3-ol ili njegovih prekursora uz pomoć karbamoilcije uz korišćenje agensa za spajanje sa ciljem dobivanja jedinjenja sa formulom (6)gde pomenuti prekursor (3R, 3aS, 6aR)-heksahidrofuro [2, 3-b] furan-3-ol obuhvata jedinjenja gde kiseonik iz alkoholne funkcije je zaštićen sa O-zaštitnim grupama, izabranima iz t-butil etera, acetata, benzilnih grupa, benzilnih etera, allila, silil zaštitnih grupa, alkoksialkilnih grupa tetrahidropiranila.Prijava sadrži još 13 patentnih zahteva.
YUP-2009/0404A 2003-12-23 2004-12-23 Proces za pripremanje (3r,3as,6ar)-heksahidrofuro│2,3-b│ furan-3-il (1s,2r)-3-││(4-aminofenil) sulfonil│(izobutil) amino │-1-benzil-2-hidroksipropilkarbamata RS51073B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03104949 2003-12-23
US56818304P 2004-05-04 2004-05-04
PCT/EP2004/053692 WO2005063770A1 (en) 2003-12-23 2004-12-23 Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate

Publications (1)

Publication Number Publication Date
RS51073B true RS51073B (sr) 2010-10-31

Family

ID=43827001

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2009/0404A RS51073B (sr) 2003-12-23 2004-12-23 Proces za pripremanje (3r,3as,6ar)-heksahidrofuro│2,3-b│ furan-3-il (1s,2r)-3-││(4-aminofenil) sulfonil│(izobutil) amino │-1-benzil-2-hidroksipropilkarbamata

Country Status (5)

Country Link
US (1) US7772411B2 (sr)
JP (1) JP4818124B2 (sr)
ME (1) ME01059B (sr)
RS (1) RS51073B (sr)
UA (1) UA85567C2 (sr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2217548A1 (en) * 2007-10-26 2010-08-18 Concert Pharmaceuticals Inc. Deuterated darunavir
US8592487B2 (en) * 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
TWI482775B (zh) * 2008-09-01 2015-05-01 Tibotec Pharm Ltd 用於製備（３ｒ，３ａｓ，６ａｒ）－六氫呋喃并〔２，３－ｂ〕呋喃－３－基（１ｓ，２ｒ）－３－〔〔（４－胺基苯基）磺醯基〕（異丁基）胺基〕－１－苯甲基－２－羥基丙基胺基甲酸酯之方法
EP2358198A4 (en) * 2008-10-24 2012-11-14 Concert Pharmaceuticals Inc HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
WO2010127272A2 (en) * 2009-04-30 2010-11-04 Concert Pharmaceuticals, Inc. Hydroxyethylamino sulfonamide derivatives
WO2011005502A2 (en) 2009-06-23 2011-01-13 Biolex Therapeutics, Inc. Methods and compositions for the cryopreservation of duckweed
WO2011017395A1 (en) * 2009-08-04 2011-02-10 Glaxosmithkline Llc Chemical compounds
WO2011051978A2 (en) 2009-10-30 2011-05-05 Lupin Limited A novel process for preparation of darunavir and darunavir ethanolate of fine particle size
AU2011210349A1 (en) 2010-01-28 2012-07-05 Mapi Pharma Limited Process for the preparation of darunavir and darunavir intermediates
WO2012107889A1 (en) 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Process for the preparation of amorphous darunavir
WO2013011485A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors
EP2804869B1 (en) 2012-01-18 2019-06-12 Aurobindo Pharma Limited Novel solvates of darunavir
EP2867210A1 (en) * 2012-07-02 2015-05-06 Pharmathen S.A. A process for the preparation of solifenacin or a salt thereof
ES2848216T3 (es) 2012-07-24 2021-08-05 Laurus Labs Ltd Un proceso para la preparación de Darunavir
US9551373B2 (en) 2014-06-27 2017-01-24 The Boeing Company Apparatus for fuel tank spark containment
US20160075643A1 (en) 2014-09-16 2016-03-17 Zcl Chemicals Limited Novel process to prepare intermediates of hiv-protease inhibitors thereof
JP6435907B2 (ja) * 2015-02-16 2018-12-12 住友化学株式会社 ヘキサヒドロフロフラノール誘導体の製造方法
EP3303343A1 (en) 2015-06-05 2018-04-11 Amneal Pharmaceuticals Company GmbH Process for the preparation of darunavir
EP3518935A1 (en) 2016-09-27 2019-08-07 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
EP3532478B1 (en) 2016-10-27 2021-05-26 Gilead Sciences, Inc. Crystalline form of darunavir free base
PL3541819T3 (pl) * 2016-11-17 2021-06-14 Janssen Sciences Ireland Unlimited Company Uproszczona procedura wytwarzania darunawiru
CN113896658A (zh) * 2021-09-24 2022-01-07 上药康丽（常州）药业有限公司 一种利用微通道反应器合成地瑞那韦中间体的方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0129856A3 (de) 1983-06-21 1985-12-18 Lobenstein & Ludwig Verfahren und Vorrichtung zur Herstellung von Presslingen aus zerkleinerten Produktionsruckständen und Abfällen
EP0656887B1 (en) 1992-08-25 1998-10-28 G.D. Searle & Co. Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
EP0715618B1 (en) 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
DE69637380T2 (de) 1995-01-20 2009-09-17 G.D. Searle Llc, Chicago Bis-sulfonamid-hydroxyethylamino-derivate als inhibitoren retroviraler proteasen
US5929284A (en) 1995-02-03 1999-07-27 Kaneka Corporation Processes for producing α-halo ketones, α-halohydrins and epoxides
US5756533A (en) 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5705500A (en) 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
WO1996028465A1 (en) 1995-03-10 1996-09-19 G.D. Searle & Co. Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
WO1997018205A1 (en) 1995-11-15 1997-05-22 G.D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
DE69619067T2 (de) 1995-11-17 2002-10-02 Ajinomoto Kk Verfahren zur Herstellung von 3-Amino-2-oxo-1-Halogenpropan-Derivaten
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
JP3622983B2 (ja) 1996-08-23 2005-02-23 ギリアード サイエンシーズ， インコーポレイテッド シクロヘキセンカルボキシレート誘導体の調製
GB9805898D0 (en) * 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
JP4776775B2 (ja) 1998-06-23 2011-09-21 アメリカ合衆国 Ｈｉｖ感染哺乳動物を治療するための医薬組成物
US6344572B1 (en) 1999-01-29 2002-02-05 Kaneka Corporation Processes for the preparation of threo-1,2-epoxy-3-amino-4-phenylbutane derivatives
DE60024419T2 (de) * 1999-02-12 2006-08-17 Vertex Pharmaceuticals Inc., Cambridge Aspartyl-protease-inhibitoren
KR100339831B1 (ko) * 1999-08-18 2002-06-07 김태성 신규의 에틸 아지리딘 유도체 및 그 제조방법
KR100708221B1 (ko) 1999-08-31 2007-04-17 아지노모토 가부시키가이샤 에폭사이드 결정의 제조방법
EP2194038A3 (en) 1999-12-23 2010-09-01 Ampac Fine Chemicals LLC Improved preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-P-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
US6455738B1 (en) 2000-07-13 2002-09-24 Rhodia Chimie Process for the sulfonation of an aromatic compound
KR20020046948A (ko) 2000-12-12 2002-06-21 에가시라 구니오 에폭사이드 결정의 제조방법
AU2002310818B2 (en) 2001-05-11 2007-12-13 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-amino-benzoxazole sulfonamide HIV protease inhibitors
ATE453648T1 (de) 2001-09-10 2010-01-15 Tibotec Pharm Ltd Verfahren zur herstellung von hexahydrofuroc2,3- büfuran-3-ol
KR100927304B1 (ko) 2001-12-27 2009-11-18 다이이찌 세이야꾸 가부시기가이샤 β-아밀로이드 단백 생산·분비 저해제
AU2002362189A1 (en) * 2001-12-28 2003-07-24 Ajinomoto Co., Inc. Process for producing crystal of benzenesulfonamide derivative, and novel crystal of intermediate therefor and process for producing the same
ES2638412T3 (es) 2002-05-16 2017-10-20 Janssen Sciences Ireland Uc Formas pseudopolimórficas de un inhibidor de la proteasa del HIV

Also Published As

Publication number Publication date
UA85567C2 (en) 2009-02-10
JP2007520468A (ja) 2007-07-26
US7772411B2 (en) 2010-08-10
ME01059B (me) 2012-10-20
JP4818124B2 (ja) 2011-11-16
US20070060642A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
RS51073B (sr) Proces za pripremanje (3r,3as,6ar)-heksahidrofuro│2,3-b│ furan-3-il (1s,2r)-3-││(4-aminofenil) sulfonil│(izobutil) amino │-1-benzil-2-hidroksipropilkarbamata
US10934307B2 (en) Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B
US10913749B2 (en) Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
US11136335B2 (en) Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
Bensoussan et al. Iron-catalyzed cross-coupling between C-bromo mannopyranoside derivatives and a vinyl Grignard reagent: Toward the synthesis of the C31–C52 fragment of amphidinol 3
HRP20170392T1 (hr) Postupak za pripremu darunavira i njegovog amorfnog oblika
BR0212458A (pt) Composto ou sal farmaceuticamente aceitável, ou um éster hidrolizável in vivo deste, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto ou sal farmaceuticamente aceitável, ou um éster hidrolizável in vivo deste, composição farmacêutica, e, processo para a preparação de um composto ou sais farmaceuticamente aceitável, ou ésteres hidrolizáveis in vivo deste
ES2516916T3 (es) Procedimiento para la preparación de darunavir e intermedios de darunavir
JP2021509665A (ja) ハリコンドリンマクロライドとそのアナログの合成に有用なプリンス反応及び化合物
Ghosh et al. Cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors
CN101104610A (zh) 4-脱氧异鬼臼毒素衍生物及其制备方法和医药用途
WO2005000249A3 (en) Preparation of chemical compounds
RU2777913C2 (ru) Реакция принса и промежуточные продукты, применимые при синтезе макролидов галихондринового ряда и их аналогов
WO2007006707A1 (en) 1- [2' , 3' -dideoxy-3' c- (hydroxymethyl) - beta-d-erythro-pentofuranosyl] cytosine derivatives as hiv inhibitors